Compare Moderna, Inc. (MRNA) vs Cactus Inc. Class A Common Stock (WHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Cactus Inc. Class A Common Stock — how do they compare? Moderna, Inc. trades at $241.3 (market cap $90.35B), while Cactus Inc. Class A Common Stock trades at $61.66 (market cap $5.02B). The key difference: Moderna, Inc. is far larger — about 18× Cactus Inc. Class A Common Stock's market cap, and Cactus Inc. Class A Common Stock pays a 0.96% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Cactus Inc. Class A Common Stock for 0 Days on average.
| MRNA | WHD | |
|---|---|---|
Market Cap | $90.35B | $5.02B |
Volume | 16,579,584 | 804,573 |
Sector | Health | Energy |
52-Week High | $226.30 | $73.73 |
52-Week Low | $22.36 | $35.26 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $86.50B | $4.71B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative net income margins (-142.58%) and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock has rallied over 500% in 2026, creating valuation concerns with a P/S ratio of 40.29.
While Nasdaq inclusion and cancer vaccine pipeline progress offer upside potential, Moderna's high valuation and persistent losses present significant risk. Analyst consensus is mixed with a $115.70 price target below current levels, indicating cautious sentiment despite recent momentum. Investors face tension between growth prospects and financial sustainability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Cactus Inc. Class A Common Stock
Cactus Inc. designs, manufactures, and rents wellhead and pressure control equipment for oil and gas drilling, completion, and production, operating under the Cactus Wellhead brand.
Read more on WHD →
